APA (7th ed.) Citation

Lodise, T., Colman, S., Alexander, E., Stein, D., Fitts, D., Goldberg, L., & Schranz, J. (2019). 676. Health-Related Quality of Life (HRQoL) as Measured by the 12-Item Medical Outcomes Study Short-Form (SF-12) Among Adults With Community-Acquired Bacterial Pneumonia (CABP) Who Received Either Lefamulin (LEF) or Moxifloxacin (MOX) in Two Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trials (LEAP 1 and 2). Open Forum Infectious Diseases, 6, S308. https://doi.org/10.1093/ofid/ofz360.744

Chicago Style (17th ed.) Citation

Lodise, Thomas, Sam Colman, Elizabeth Alexander, Daniel Stein, David Fitts, Lisa Goldberg, and Jennifer Schranz. "676. Health-Related Quality of Life (HRQoL) as Measured by the 12-Item Medical Outcomes Study Short-Form (SF-12) Among Adults With Community-Acquired Bacterial Pneumonia (CABP) Who Received Either Lefamulin (LEF) or Moxifloxacin (MOX) in Two Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trials (LEAP 1 and 2)." Open Forum Infectious Diseases 6 (2019): S308. https://doi.org/10.1093/ofid/ofz360.744.

MLA (9th ed.) Citation

Lodise, Thomas, et al. "676. Health-Related Quality of Life (HRQoL) as Measured by the 12-Item Medical Outcomes Study Short-Form (SF-12) Among Adults With Community-Acquired Bacterial Pneumonia (CABP) Who Received Either Lefamulin (LEF) or Moxifloxacin (MOX) in Two Phase 3 Randomized, Double-Blind, Double-Dummy Clinical Trials (LEAP 1 and 2)." Open Forum Infectious Diseases, vol. 6, 2019, p. S308, https://doi.org/10.1093/ofid/ofz360.744.